Page 38 - Oncology Coder News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Oncology coder. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Oncology Coder Today - Breaking & Trending Today

FDA Approved Fifth Bevacizumab Biosimilar, Avzivi

Bio-Thera Solutions’ Avzivi (bevacizumab-tnjn) has become the fifth biosimilar referencing Avastin (bevacizumab) to be approved in the United States. ....

United States , Li Zhang , Genentech Avastin , Bio Thera Solutions , Bio Thera Solution Avzivi ,

Candelight remembrance ceremony set for Wednesday

MANKATO — A community candle-lighting ceremony to commemorate those experiencing a life challenge or honor a loved one’s memory takes place 6 p.m. Wednesday at Good Counsel Chapel, 170 Good ....

Jonathan Zierdt Cancer Fund , Mankato Area Foundation , Good Counsel Chapel , Parea Foundation ,

Atezolizumab Monotherapy vs Chemotherapy In Advanced Urothelial Carcinoma

1. The median overall survival was similar between both groups, 15.2 months in atezolizumab monotherapy vs 13.3 months in chemotherapy, with HR 0.98. 2. Atezolizumab monotherapy was better tolerated, with 16% experiencing grade 3–4 treatment-related adverse events compared to 80% in chemotherapy. Evidence Rating Level: 1 (Excellent) Study Rundown: Cisplatin-based chemotherapy is the standard of ....

Rating Level , Advanced Urothelial Carcinoma , Cisplatin Ineligible , Chronic Disease ,

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) prescribed for type 2 diabetes are associated with reduced colorectal cancer (CRC) risk compared to other antidiabetic agents

1. In all patients, there was a 44% reduction in risk of colorectal cancer when using GLP-1RAs as compared to insulin, and a 25% reduction in risk as compared to metformin use. 2. Results for overweight patients and those with obesity showed GLP-1RAs significantly reduced risk for CRC compared with multiple antidiabetics. Evidence Rating Level: ....

Minute Medicine Inc , Rating Level , Colorectal Cancer Crc , Glp 1 Receptor Agonists , Chronic Disease ,

Mirvetuximab soravtansine-gynx compared to chemotherapy in folate receptor alpha-positive platinum resistant ovarian cancer led to improved survival

1. Mirvetuximab soravtansine-gynx (MIRV), significantly improved progression-free survival, objective response, and overall survival compared to chemotherapy in patients with platinum-resistant, folate receptor alpha (FRα)-positive ovarian cancer 2. Ocular adverse events were more common with MIRV, which included blurry vision, keratopathy, and dry eyes. Evidence Rating: Level 1 (Excellent) Study rundown: Mirvetuximab soravtansine-gynx (MIRV), is an ....

Folate Receptor Alpha , Mirvetuximab Soravtansine Gynx , Platinum Resistant Recurrent Ovarian Cancer , Chronic Disease ,